Monthly Archives: July 2015

Naurex

Over the weekend, Naurex announced that it had been acquired by Allergan (Actavis/Forest) for $560 million plus undisclosed milestones; Allergan is focused upon Naurex’s two clinical-stage Rapid-Acting-Antidepressant candidates, IV rapastinel/GlyX-13, and orally-bioavailable NRX-1074. NIR has been following this particular technology … Continue reading

Posted in Big Pharma, Biotech | Tagged , , , | Leave a comment

mAbMEN: It’s Not Over

Eli Lilly: Experimental Alzheimer’s drug shows some benefit  (AP) Eli Lilly’s Solanezumab Is the Alzheimer’s Drug Equivalent of the Internet Dress                (TheStreet) Lilly says drug slows Alzheimer’s in patients with mild disease (Reuters) Lilly’s Alzheimer’s Drug May Slow Patients’ Decline … Continue reading

Posted in Big Pharma, BioFollies, Biotech, Science | Tagged , , , , | Leave a comment

Walking It Back on Axovant

NeuroPerspective subscribers are aware that we have not been unreservedly enthused about Axovant; its 5HT-6 drug for Alzheimer’s (licensed from GSK); and their ‘biggest CNS IPO ever.’ There has been a genuine element of fervid overheating here, but unfortunately, the … Continue reading

Posted in Uncategorized | Leave a comment